 saw their share price rise again on Thursday, boosting gains accumulated earlier on in the week.){kind=link}
GlaxoSmithKline (LON:GSK) saw their share price rise again on Thursday, boosting gains accumulated earlier on in the week.
The company saw their share price rise higher yesterday after announcing it had received regulatory approval for their new lung cancer drug Trelegy Ellipta. This new development is likely to put them back in the lead for respiratory pharmaceuticals, after falling sales of its older drug Advair which recently lost its patent.
Trelegy Ellipta is the first once-daily triple medicine for chronic obstructive pulmonary disease (COPD), putting Britain’s biggest drugmaker ahead of rivals such as AstraZeneca and Novartis.
Patrick Vallance, President R&D, GSK, said of the results:
“We are delighted with the positive results achieved in the IMPACT study. This is the first study to report a comparison of a single inhaler triple therapy with two dual therapies, providing much needed clinical evidence about the ability of a single inhaler triple therapy to reduce exacerbations.
“It is important to note that all treatments were comprised of different combinations of the same component molecules administered in the same Ellipta inhaler, in a single dose, once a day to allow direct treatment comparisons. We hope these results will inform global guidelines and look forward to sharing the results with regulatory authorities. We will continue to analyse the wealth of data generated to further the understanding of the treatment of COPD.”
The positive results from GSK come as the NHS announces it will start to offer life-extending lung cancer drug nivolumab which is aimed at later stage lung cancer.